IMRX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	338 325
平均成交量	754 996
市值	48.63M
EPS	$-0.520 ( 2024-05-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.870
ATR14	$0.00200 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Cormorant Asset Management, Lp	Sell	100	Class A Common Stock
2024-04-01	Cormorant Asset Management, Lp	Sell	300	Class A Common Stock
2024-04-01	Cormorant Asset Management, Lp	Sell	100	Class A Common Stock
2024-04-01	Cormorant Asset Management, Lp	Sell	600	Class A Common Stock
2024-04-01	Cormorant Asset Management, Lp	Sell	10	Class A Common Stock

INSIDER POWER
6.35
Last 92 transactions
Buy: 3 241 516 \| Sell: 1 367 921

音量相关性

長: 0.25 (neutral)

短: -0.13 (neutral)

Signal:(53.257) Neutral

Immuneering Corporation 相关性

10 最正相关
CPSH	0.958
RGF	0.956
PHCF	0.955
PAIC	0.952
WKSP	0.95
SVAC	0.945
PRTS	0.942
JRJC	0.942
TIL	0.941
BLPH	0.933

10 最负相关
NETE	-0.972
GRCL	-0.959
MMAC	-0.953
VITL	-0.951
SASR	-0.949
MNMD	-0.947
MIRO	-0.945
DXPE	-0.943
BSRR	-0.942
GIFI	-0.942

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Immuneering Corporation 相关性 - 货币/商品

0.32
( neutral )

0.25
( neutral )

0.00
( neutral )

0.36
( neutral )

-0.34
( neutral )

Immuneering Corporation 财务报表

Annual	2023
营收:	$0
毛利润:	$-764 138 (0.00 %)
EPS:	$-1.880

FY	2023
营收:	$0
毛利润:	$-764 138 (0.00 %)
EPS:	$-1.880

FY	2022
营收:	$316 952
毛利润:	$158 830 (50.11 %)
EPS:	$-1.870

FY	2021
营收:	$2.08M
毛利润:	$927 000 (44.57 %)
EPS:	$-2.46

Financial Reports:

No articles found.

Immuneering Corporation

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.